The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s disease
Science Translational Medicine · 18.01.2023 · 15 (679)
DOI: 10.1126/scitranslmed.abp9352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 18.01.2023. Verfasst von Senthilkumar S Karuppagounder und 18 weiteren Autor:innen. Beteiligte Einrichtung: Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Neurodegenerative Diseases, Synucleinopathies. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease of the central nervous system, with an estimated 5,000,000 cases worldwide. PD pathology is characterized by the accumulation of misfolded α-synuclein, which is thought to play a critical role in the pathogenesis of the disease. Animal models of PD suggest that activation of Abelson tyrosine kinase (c-Abl) plays an essential role in the initiation and progression of α-synuclein pathology and initiates processes leading to degeneration of dopaminergic and nondopaminergic neurons. Given the potential role of c-Abl in PD, a c-Abl inhibitor library was developed to identify orally bioavailable c-Abl inhibitors capable of crossing the blood-brain barrier based on predefined characteristics, leading to the discovery of IkT-148009. IkT-148009, a brain-penetrant c-Abl inhibitor with a favorable toxicology profile, was analyzed for therapeutic potential in animal models of slowly progressive, α-synuclein–dependent PD. In mouse models of both inherited and sporadic PD, IkT-148009 suppressed c-Abl activation to baseline and substantially protected dopaminergic neurons from degeneration when administered therapeutically by once daily oral gavage beginning 4 weeks after disease initiation. Recovery of motor function in PD mice occurred within 8 weeks of initiating treatment concomitantly with a reduction in α-synuclein pathology in the mouse brain. These findings suggest that IkT-148009 may have potential as a disease-modifying therapy in PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
- Inhibikase Therapeutics Inc., Atlanta, GA 30339, USA.
- Zanvyl Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD 21218, USA.
- Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
- Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
ORCID-Profile: Senthilkumar S Karuppagounder, Roger Rush, Shivani Bisen, Yoko Yamashita, Nicholas Sloan, Alexander Sigmon, Hyeun Woo Lee, Shirley Marino Lee, Leslie Watkins, Ted M Dawson, Valina L Dawson
Förderung
- NINDS NIH HHS
Zitieren
APA
Karuppagounder, S. S., Wang, H., Kelly, T., Rush, R., Nguyen, R., Bisen, S., Yamashita, Y., Sloan, N., Dang, B., Sigmon, A., Lee, H. W., Marino Lee, S., Watkins, L., Kim, E., Brahmachari, S., Kumar, M., Werner, M. H., Dawson, T. M., & Dawson, V. L. (2023). The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s disease. Science Translational Medicine, 15(679). https://doi.org/10.1126/scitranslmed.abp9352
Vancouver
Karuppagounder SS, Wang H, Kelly T, Rush R, Nguyen R, Bisen S, et al. The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s disease. Science Translational Medicine. 2023;15(679). doi:10.1126/scitranslmed.abp9352
BibTeX
@article{Karuppagounder2023,
author = {Karuppagounder, Senthilkumar S and Wang, Hu and Kelly, Terence and Rush, Roger and Nguyen, Richard and Bisen, Shivani and Yamashita, Yoko and Sloan, Nicholas and Dang, Brianna and Sigmon, Alexander and Lee, Hyeun Woo and Marino Lee, Shirley and Watkins, Leslie and Kim, Erica and Brahmachari, Saurav and Kumar, Manoj and Werner, Milton H and Dawson, Ted M and Dawson, Valina L},
title = {The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s disease},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {679},
doi = {10.1126/scitranslmed.abp9352}
}
EUVIMED